Hyperthermic intraperitoneal chemotherapy after upfront cytoreductive surgery for stage <scp>III</scp> epithelial ovarian cancer: Follow‐up of long‐term survival
The updated results indicate that the addition of HIPEC is associated with improved long-term survival outcomes beyond 5 years for patients with stage III epithelial ovarian cancer in the upfront setting.
Authors
- Yangxiao Chen (ORCID: https://orcid.org/0000-0002-1015-0649)
- Xianzi Yang (ORCID: https://orcid.org/0000-0002-0365-0135)
- Jinfu He
- Shuzhong Cui (ORCID: https://orcid.org/0000-0003-2178-8741)
- Boni Ding (ORCID: https://orcid.org/0000-0003-1319-1398)
- Run-ya Fang
- Ke Wang (ORCID: https://orcid.org/0000-0003-2942-7676)
- Jun Tian (ORCID: https://orcid.org/0000-0003-3337-9451)
- Jiali Luo (ORCID: https://orcid.org/0000-0002-4130-7039)
- Yingsi Wang
- Li Wang (ORCID: https://orcid.org/0000-0002-8969-7427)
- Yue Wang (ORCID: https://orcid.org/0000-0002-4181-9018)
- Ziying Lei (ORCID: https://orcid.org/0000-0002-7734-5352)
- Hongsheng Tang (ORCID: https://orcid.org/0009-0005-5146-618X)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Zhengzhou University (CN)
- Henan University Huaihe Hospital and Huaihe Clinical Institute (CN)
- Henan Provincial People's Hospital (CN)
- Henan Cancer Hospital (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Acta Obstetricia Et Gynecologica Scandinavica
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1111/aogs.15094
- Citations
- 4
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.79
Funders
- National Natural Science Foundation of China